S. Nugteren

High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence

G. Meijer, H. Stockmann, J. Samsom, 2022, Scientific Reports.

Secretory Leukocyte Protease Inhibitor (SLPI) in mucosal tissues: Protects against inflammation, but promotes cancer.

J. Samsom, S. Nugteren, 2021, Cytokine & growth factor reviews.

Duplication of the IL2RA locus causes excessive IL-2 signaling and may predispose to very early onset colitis

M. Mearin, N. Cerf-Bensussan, J. Nowak, 2021, Mucosal Immunology.

Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis

G. Meijer, J. Samsom, J. Sanders, 2020, Oncoimmunology.

Endogenous secretory leukocyte protease inhibitor inhibits microbial‐induced monocyte activation

J. Samsom, Y. Simons‐Oosterhuis, S. Nugteren, 2022, European journal of immunology.

Colitis and lower abdominal mass by Actinomyces israelii in a patient with an IUD.

M. Straub, R. Ouwendijk, A. Dees, 1996, The Netherlands journal of medicine.